Effect of nebulized furosemide in terminally ill cancer patients with dyspnea

Journal of Pain and Symptom Management

Volumn 26, Issue 4, 2003, Pages 962-967

  Kohara, Hiroyuki ^a   Ueoka, Hiroshi ^b   Aoe, Keisuke ^a   Maeda, Tadashi ^a   Takeyama, Hiroyasu ^a   Saito, Ryusei ^c   Shima, Yasuo ^d   Uchitomi, Yosuke ^e  

^a NATIONAL SANYO HOSPITAL   (Japan)

^b OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^c National Nishi Gunma Hospital   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^e NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Cancer; Cancer Dyspnea Scale; Dyspnea; Nebulized furosemide

Indexed keywords

BUPRENORPHINE; CODEINE; CORTICOSTEROID; FUROSEMIDE; MORPHINE; OXYGEN;

ADULT; AGED; ANXIETY; ARTERIAL GAS; ARTICLE; BREATHING RATE; CANCER PATIENT; CARBON DIOXIDE TENSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG EFFECT; DRUG EFFICACY; DYSPNEA; EVALUATION; FEMALE; HEART RATE; HUMAN; MALE; NAUSEA; NEBULIZER; OXYGEN SATURATION; OXYGEN TENSION; OXYGEN THERAPY; SIDE EFFECT; SOMNOLENCE; STATISTICAL SIGNIFICANCE; TERMINALLY ILL PATIENT; TREATMENT OUTCOME;

EID: 0141758378     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(03)00322-1     Document Type: Article

References (18)

1. Cowcher K., Hanks G.W. Long-term management of respiratory symptoms in advanced cancer. J Pain Symptom Manage. 5:1990;320-330.
2. Manning H.L., Schwartzstein R.M. Pathophysiology of dyspnea. N Engl J Med. 333:1995;1547-1553.
3. Bruera E., Ripamonti C. Dyspnea in patients with advanced cancer. Berger A., Portenoy R.K., Weissman D.E. Principles and practice of supportive oncology. 23:1998;295-308 Lippincott-Raven, Philadelphia.
4. Higginson I., McCarthy M. Measuring symptoms in terminal cancer: are pain and dyspnea controlled? J R Soc Med. 82:1989;264-267.
5. Ruben D.B., Mor M. Dyspnea in terminal cancer patients. Chest. 89:1986;234-236.
6. Maltoni M., Pirovano M., Scarpi E., et al. Prediction of survival of patients terminally ill with cancer. Cancer. 75:1995;2613-2622.
7. Bruera E., Schmitz B., Pither J., et al. The frequency and correlates of dyspnea in patients with advanced cancer. J Pain Symptom Manage. 19:2000;357-362.
8. Bianco S., Vaghi A., Robushi M., et al. Prevention of exercise-induced bronchoconstriction by inhaled furosemide. Lancet. 2:1988;252-255.
9. Bianco S., Pieroni M.G., Refini R.M., et al. Protective effect of inhaled furosemide on allergen-induced early and late asthmatic reactions. N Engl J Med. 321:1989;1069-1073.
10. Nishino T., Ide T., Sudo T., et al. Inhaled furosemide greatly alleviates the sensation of experimentally induced dyspnea. Am J Respir Crit Care Med. 161:2000;1963-1967.
11. Stone P., Kurowska A., Schwartzstein M. Nebulized furosemide for dyspnea. Palliat Med. 8:1994;258.
12. Twycross R. Respiratory symptom. Twycross R. Symptom management in advanced cancer. 1994;129-142 Radcliff Medical Press, Oxford.
13. Muza S.R., Silverman M.T., Gilmore G.C., et al. Comparison of scales used to quantitate the sense of effort to breath in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 141:1990;909-913.
14. Tanaka K., Akechi T., Okuyama T., et al. Development and validation of the cancer dyspnoea scale: a multidimensional, brief, self-rating scale. Br J Cancer. 82:2000;800-805.
15. Escalante C.P., Martin C.G., Elting L.S., et al. Dyspnea in cancer patients. Etiology, resource utilization and survival-implications in a managed care world. Cancer. 78:1996;1314-1319.
16. Shimoyama M., Shimoyama M. Nebulized furosemide as a novel treatment for dyspnea in terminal cancer patients. J Pain Symptom Manage. 23:2002;73-76.
17. O'Connor B.J., Chung K.F., Chen-Worsdell Y.M., et al. Effect of inhaled furosemide and bumetanide on adenosine 5[prime]-monophosphate- and sodium metabisulfite-induced bronchoconstriction in asthmatic subjects. Am Rev Respir Dis. 143:1991;1329-1333.
18. Robuschi M., Gambaro G., Spagnotto S., et al. Inhaled furosemide is highly effective in preventing ultrasonically nebulized water bronchoconstriction. Pulm Pharmacol. 1:1987;187-191.